Investors see a potential biotech rebound in 2026 as IPO activity, dealmaking and lower rates offset lingering policy risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback